Metraipolis › archive › dc_2d145edd35ca

A Dangerous Partnership: Malignancy and Antiphospholipid Antibodies — Europe PMC PMID:42568225

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/42568225
DOI: 10.5152/eurasianjmed.2026.261434
License (as archived): solo-consultazione
Archived: 2026-10-17T13:18:44.101Z
SHA-256 of the archived text: 2cbdd6b1cce46150c6a5ff1b0818ad0a791556ebabc81af7a36ac5b5d6ae2e70
Stable URL of this page: https://metraipolis.com/documento/dc_2d145edd35ca

How to cite

A Dangerous Partnership: Malignancy and Antiphospholipid Antibodies — Europe PMC PMID:42568225 — Europe PMC (en), https://europepmc.org/article/MED/42568225 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_2d145edd35ca (Metraipolis archive dc_2d145edd35ca, sha256 2cbdd6b1cce46150c6a5ff1b0818ad0a791556ebabc81af7a36ac5b5d6ae2e70)

BibTeX

@misc{dc2d145edd35ca,
  title = {A Dangerous Partnership: Malignancy and Antiphospholipid Antibodies — Europe PMC PMID:42568225},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42568225},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_2d145edd35ca; sha256 2cbdd6b1cce46150c6a5ff1b0818ad0a791556ebabc81af7a36ac5b5d6ae2e70},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42568225. Agents can read the archived copy with the MCP tool read_document.